BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26597881)

  • 1. Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.
    Johnson C; Huynh V; Hargrove L; Kennedy L; Graf-Eaton A; Owens J; Trzeciakowski JP; Hodges K; DeMorrow S; Han Y; Wong L; Alpini G; Francis H
    Am J Pathol; 2016 Jan; 186(1):123-33. PubMed ID: 26597881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
    Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
    Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.
    Kennedy LL; Hargrove LA; Graf AB; Francis TC; Hodges KM; Nguyen QP; Ueno Y; Greene JF; Meng F; Huynh VD; Francis HL
    Lab Invest; 2014 Dec; 94(12):1406-18. PubMed ID: 25365204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
    Francis H; DeMorrow S; Venter J; Onori P; White M; Gaudio E; Francis T; Greene JF; Tran S; Meininger CJ; Alpini G
    Gut; 2012 May; 61(5):753-64. PubMed ID: 21873469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.
    Pei YF; Liu J; Cheng J; Wu WD; Liu XQ
    Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.
    Visciano C; Liotti F; Prevete N; Cali' G; Franco R; Collina F; de Paulis A; Marone G; Santoro M; Melillo RM
    Oncogene; 2015 Oct; 34(40):5175-86. PubMed ID: 25619830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.
    Zhou T; Meadows V; Kundu D; Kyritsi K; Owen T; Ceci L; Carpino G; Onori P; Gaudio E; Wu N; Glaser S; Ekser B; Alpini G; Kennedy L; Francis H
    Hepatol Commun; 2022 Oct; 6(10):2715-2731. PubMed ID: 35799467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Kyritsi K; Kennedy L; Meadows V; Hargrove L; Demieville J; Pham L; Sybenga A; Kundu D; Cerritos K; Meng F; Alpini G; Francis H
    Hepatology; 2021 Jun; 73(6):2397-2410. PubMed ID: 32761972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
    Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
    Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
    Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
    Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
    Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
    Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.
    Yang H; Lu X; Liu Z; Chen L; Xu Y; Wang Y; Wei G; Chen Y
    Oncotarget; 2015 Mar; 6(8):6310-25. PubMed ID: 25749036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
    Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of hepatic mast cells from cholestatic rats.
    Hargrove L; Graf-Eaton A; Kennedy L; Demieville J; Owens J; Hodges K; Ladd B; Francis H
    Lab Invest; 2016 Nov; 96(11):1198-1210. PubMed ID: 27548803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Shu L; Li X; Liu Z; Li K; Shi A; Tang Y; Zhao L; Huang L; Zhang Z; Zhang D; Huang S; Lian S; Sheng G; Yan Z; Zhang Z; Xu Y
    Hepatology; 2024 Feb; 79(2):307-322. PubMed ID: 37140231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
    Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
    Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Shi A; Liu Z; Fan Z; Li K; Liu X; Tang Y; Hu J; Li X; Shu L; Zhao L; Huang L; Zhang Z; Lv G; Zhang Z; Xu Y
    Gut; 2024 Mar; ():. PubMed ID: 38458750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.